Clinical Trials
16 trialsNCT05985655 2026-04-23
ELUCIDATE
Exscientia AI Limited
Phase 1/2 Recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT05059444 2025-08-22
ORACLE
Guardant Health, Inc.
Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05788484 2025-06-15
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT04440943 2023-06-18
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT02262455 2017-02-13
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed